Literature DB >> 11745701

NG2/HMPG modulation of human articular chondrocyte adhesion to type VI collagen is lost in osteoarthritis.

K S Midwood1, D M Salter.   

Abstract

NG2/human melanoma proteoglycan (HMPG) is a chondroitin sulphate proteoglycan (CSPG), expressed by chondrocytes in fetal and in normal and osteoarthritic (OA) adult articular cartilage. NG2/HMPG is a receptor for extracellular matrix proteins, including type VI collagen, and regulates beta1 integrin binding to fibronectin. This study was undertaken to identify whether NG2/HMPG had similar activities in human articular chondrocytes (HACs). Normal and OA adult HAC adhesion to fibronectin, type II or type VI collagen was assessed using a methylene blue assay. The requirement for integrins, NG2/HMPG, and integrin-associated signalling molecules was investigated using anti-beta1 integrin and anti-HMPG antibodies and pharmacological inhibitors of signalling molecules. The adhesion of normal and OA HACs to fibronectin, type II and type VI collagen was beta1 integrin-dependent. Normal HAC adhesion to type VI collagen was stimulated by anti-HMPG antibodies. This effect was inhibited by pertussis toxin. Anti-HMPG antibodies had no effect on OA chondrocyte adhesion to type VI collagen, or on normal and OA cell adhesion to fibronectin and type II collagen. The results show that NG2/HMPG modulates integrin-mediated interactions of normal HACs with type VI collagen. Loss of this activity may be of importance in the progression of osteoarthritis. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745701     DOI: 10.1002/path.985

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

1.  RECK is up-regulated and involved in chondrocyte cloning in human osteoarthritic cartilage.

Authors:  Tokuhiro Kimura; Aiko Okada; Taku Yatabe; Masashi Okubo; Yoshiaki Toyama; Makoto Noda; Yasunori Okada
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

2.  Accumulation of type VI collagen in the primary osteon of the rat femur during postnatal development.

Authors:  Yukihiro Kohara; Satoshi Soeta; Yayoi Izu; Hajime Amasaki
Journal:  J Anat       Date:  2015-05-05       Impact factor: 2.610

3.  Harnessing cell–biomaterial interactions for osteochondral tissue regeneration.

Authors:  Kyobum Kim; Diana M Yoon; Antonios Mikos; F Kurtis Kasper
Journal:  Adv Biochem Eng Biotechnol       Date:  2012       Impact factor: 2.635

4.  NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion.

Authors:  Sabrina Cattaruzza; Pier Andrea Nicolosi; Paola Braghetta; Laura Pazzaglia; Maria Serena Benassi; Piero Picci; Katia Lacrima; Daniela Zanocco; Erika Rizzo; William B Stallcup; Alfonso Colombatti; Roberto Perris
Journal:  J Mol Cell Biol       Date:  2013-04-03       Impact factor: 6.216

5.  Functional roles of CSPG4/NG2 in chondrosarcoma.

Authors:  Nuor S M Jamil; Asim Azfer; Harrison Worrell; Donald M Salter
Journal:  Int J Exp Pathol       Date:  2016-06-12       Impact factor: 1.925

6.  Neuron/Glial Antigen 2-Type VI Collagen Interactions During Murine Temporomandibular Joint Osteoarthritis.

Authors:  Mamoru Yotsuya; Andrew E Bertagna; Nageeb Hasan; Scott Bicknell; Toru Sato; David A Reed
Journal:  Sci Rep       Date:  2019-01-11       Impact factor: 4.379

7.  Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration.

Authors:  Irwan T Makagiansar; Scott Williams; Tomas Mustelin; William B Stallcup
Journal:  J Cell Biol       Date:  2007-06-25       Impact factor: 10.539

8.  Expression of NG2 proteoglycan in the degenerated intervertebral disc in dachshunds.

Authors:  Mohammed Abdel-Hakiem; Ayuko Yamashita; Ayman Atiba; Yasuhiko Okamura; Masaaki Katayama; Haroun Youssef; Hiroshi Isomura; Yuji Uzuka
Journal:  J Vet Med Sci       Date:  2015-08-21       Impact factor: 1.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.